FCGR3A and neoplasm: In this study, UCB-NK were not tested in combination with CET due to their low surface expression of CD16a in vitro; however, UCB-NK further mature upon adoptive transfer in vivo which is accompanied by an increase in CD16a expression [50], and this feature could be exploited to enhance tumor killing even more via ADCC using CET and other IgG1 therapeutic antibodies.